The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon.
Cooksley
Graham
G
Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Brisbane, Qld, Australia. ecooksl@bigpond.com
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000032:analysis*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a